References
- Siegel R, Ward E, Brawley O, . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212–236.
- Prichard M, Harris T, Williams ME, . Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 2009;10:983–995.
- Johnston PB, Yuan R, Cavalli F, . Targeted therapy in lymphoma. J Hematol Oncol 2010;3:45.
- Schoffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009;14:559–570.
- Golsteyn RM, Schultz SJ, Bartek J, . Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5. J Cell Sci 1994;107:1509–1517.
- Golsteyn RM, Mundt KE, Fry AM, . Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol 1995;129: 1617–1628.
- Lake RJ, Jelinek WR. Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol 1993;13:7793–7801.
- Lee KS, Yuan YL, Kuriyama R, . Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol 1995;15:7143–7151.
- Mito K, Kashima K, Kikuchi H, . Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas. Leuk Lymphoma 2005;46:225–231.
- Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003;100:5789–5794.
- Steegmaier M, Hoffmann M, Baum A, . BI2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.Curr Biol 2007;17:316–322.
- Lenart P, Petronczki M, Steegmaier M, . The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007;17:304–315.
- Mross K, Frost A, Steinbild S, . Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26: 5511–5517.
- Cheson BD, Horning SJ, Coiffier B, . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
- Soto E, Staab A, Freiwald M, . Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed. Clin Pharmacol Ther 2010;88:660–667.
- Soto E, Staab A, Tillmann C, . Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development. Cancer Chemother Pharmacol 2010;66: 785–795.
- Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124–4130.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Non Hodgkin's lymphomas. Version 3. 2011. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
- Jackson JR, Patrick DR, Dar MM, . Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107–117.
- Friedberg J, Mahadevan D, Jung J, . Phase 2 trial of Alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). Blood 2011;118(Suppl. 1): Abstract 95.
- Rudolph D, Steegmaier M, Hoffmann M, . BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15:3094–3102.